Biotech Trials, IPOs, and Strategy Shifts
Kilder
- STAT: STAT+: Kyverna’s cell therapy shows lasting autoimmune benefit
- BioPharma Dive: RNAi drug specialist ADARx raises $446M IPO
- Finance: RNAi drug specialist ADARx raises $446M IPO - Yahoo Finance
- Endpoints: Acadia drug fails mid-stage study in Alzheimer's psychosis, leading to modified Phase 3
- Ctvnews: Acadia’s Alzheimer’s psychosis drug misses main goal of mid-stage study - CTV News
- Ctvnews: James Moore: David Eby’s election call is an act of desperation - CTV News
- STAT: STAT+: Why Gilead can’t stop talking about its ambitions in immunology
- STAT: Opinion: STAT+: A moment of reckoning for preventive cardiology and the precision medicine revolution
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.